Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study

• DOI: 10.1021/acs.jproteome.6b00833
• Publication Date: 2017-01-23T21:13:38Z
• Authors: Su Jong Yu; Hyunsoo Kim; Hophil Min; Areum Sohn; Young Youn Cho; Jeong-Ju Yoo; Dong Hyeon Lee; Eun Ju Cho; Jeong-Hoon Lee; Jungsoo Gim; Taesung Park; Yoon Jun Kim; Chung Yong Kim; Jung-Hwan Yoon; Youngsoo Kim
• Keywords: Proteomics; 0303 health sciences; Carcinoma, Hepatocellular; Prognosis; 12. Responsible consumption; Cohort Studies; 03 medical and health sciences; Treatment Outcome; Biomarkers, Tumor; Humans; Prospective Studies; Supervised Machine Learning; Chemoembolization, Therapeutic

This study was aimed to identify blood-based biomarkers predict a sustained complete response (CR) after transarterial chemoembolization (TACE) using targeted proteomics. Consecutive patients with HCC who had undergone TACE were prospectively enrolled (training (n = 100) and validation set 80)). Serum samples obtained before 6 months TACE. Treatment responses evaluated the modified Response Evaluation Criteria in Solid Tumors (mRECIST). In training set, MRM-MS assay identified five marker candidate proteins (LRG1, APCS, BCHE, C7, FCN3). When this five-marker panel combined best-performing clinical variables (tumor number, baseline PIVKA, AFP), resulting ensemble model highest area under receiver operating curve (AUROC) value predicting CR sets (0.881 0.813, respectively). Furthermore, an independent predictor of rapid progression (hazard ratio (HR), 2.889; 95% confidence interval (CI), 1.612–5.178; P < 0.001) overall unfavorable survival rate (HR, 1.985; CI, 1.024–3.848; 0.042) entire population by multivariate analysis. Targeted proteomics-based can outcomes Therefore, aid determining best candidates for need adjuvant therapy.